- Dr. Chunlin Yang joined Eluminex as Vice President of Technology Development
- Dr. Jinzhong Zhang was Selected as Suzhou Industrial Park Leading Talent in Science and Technology and Suzhou City Leading Talent in Science and Technology
SUZHOU, China, January 5, 2022 — Eluminex Biosciences (Suzhou) Limited (Eluminex), a venture-backed, clinical stage ophthalmology-focused biotechnology company headquartered in Suzhou, China with a U.S. subsidiary located in San Francisco Bay Area, California, announced another key senior appointment as part of the current corporate scale-up plan to support their newly opened research and development center in Suzhou BioBay.
Chunlin Yang, PhD, joined Eluminex as the Vice President of Technology Development, responsible for the research and development and commercialization of the company’s recently licensed recombinant human collagen and biosynthetic cornea technologies from the United States. With over 20 years of experience in biomaterials, biopolymers, and tissue engineering, Dr. Yang has held senior roles at FibroGen where he led the development of a biosynthetic cornea using recombinant human collagen. At Johnson & Johnson, he developed a novel biosynthetic composite technology for reconstructive surgery and soft tissue replacement and served as a Research Fellow in the Advanced Technologies and Regenerative Medicine (ATRM) unit and the Center for Biomaterials and Advanced Technologies (CBAT). His scientific accomplishments have been recognized within the industry and awarded the J&J Excellence in Science Award and has authored over 40 patent applications and more than 30 scientific papers in the fields of collagen-based biomaterials, medical devices, controlled drug delivery, and tissue engineering. Dr. Yang received his PhD in Biochemistry through the joint program of the Chinese Academy of Sciences in Beijing and Medical University of Luebeck, Germany and completed his post-doctoral fellowships at Medical University of Luebeck, the National Institutes of Health, and Thomas Jefferson University.
Jinzhong Zhang, PhD, was Selected as Suzhou Industrial Park Leading Talent in Science and Technology and Suzhou City Leading Talent in Science and Technology. Dr. Zhang is Co-founder, Chairman and CEO of Eluminex. Under his leadership, Eluminex has built one of the most globally leading teams and portfolios in the focused ophthalmology therapeutic area within a very short time. He has a long and accomplished career in the ophthalmology field and was in senior executive positions with multiple companies. He started and established his career in academic across different countries prior to joining the industry 15 years ago.
About Eluminex Biosciences
Eluminex Biosciences is a privately-held clinical-stage biopharmaceutical biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases. Eluminex is devoted towards innovating the next generation of first-in-class or best-in-class ocular therapeutics for vision-threatening or lifestyle-limiting ocular diseases. In addition to the bioengineered cornea (EB-301), Eluminex has developed a pipeline of next generation multivalent protein therapeutics for retinal diseases (EB-101, EB-102, EB-105, and EB-107) including age-related macular degeneration, macular edema, and diabetic retinopathy; these assets are wholly owned and developed by Eluminex. The Eluminex global headquarters and research and development center are located in Suzhou BioBay Industrial Park, China with a US-subsidiary located in the San Francisco Bay Area. Eluminex is supported by three premiere global life science venture funds: Lilly Asia Ventures, Hill House Capital, and Quan Capital. For more information, please visit www.eluminexbio.com.
Contact for Investors/Media:
Zhenze John Hu, PhD, MPD